SCHEMBL18220180

SCHEMBL18220180

COCCNS(=O)(=O)/C(C#N)=C(\C)c1ccc(-c2ccc3cc(NCCN4CCOCC4)ccc3c2)s1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
WNT3A P56704 5/20 0.38
FYN P06241 1/20 0.37
CNR2 P34972 1/20 0.37
MMP2 P08253 1/20 0.36
MMP8 P22894 1/20 0.36
MMP12 P39900 1/20 0.36
MMP13 P45452 1/20 0.36
POLB P06746 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
ALDH1A1 P00352 2/20 0.35
KDM4E B2RXH2 1/20 0.35
GLA P06280 1/20 0.35
GAA P10253 1/20 0.35
CYP2C9 P11712 3/20 0.35
CYP3A4 P08684 2/20 0.35
CYP1A2 P05177 1/20 0.35
MAPT P10636 1/20 0.35
HSD17B10 Q99714 1/20 0.35
SCN9A Q15858 1/20 0.35
SYK P43405 3/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25609907 0.91 FYN (0.38) WNT3AFYNCNR2POLBNPSR1
SCHEMBL18220283 0.88 KDM4E (0.38) WNT3AFYNCNR2MMP2MMP8
SCHEMBL18221453 0.87 KDM4E (0.38) WNT3AFYNCNR2MMP2MMP8
SCHEMBL23135022 0.87 FYN (0.40) WNT3AFYNALDH1A1KDM4EGLA
SCHEMBL21898274 0.86 FYN (0.35) WNT3AFYNCNR2MMP2MMP8
SCHEMBL18220182 0.86 APP (0.43) WNT3AALDH1A1KDM4EGAACYP2C9
SCHEMBL18220005 0.85 CYP2C19 (0.41) CNR2POLBNPSR1ALDH1A1KDM4E
SCHEMBL18220154 0.85 MMP2 (0.39) CNR2MMP2MMP8MMP12MMP13
SCHEMBL18220152 0.85 ALDH1A1 (0.40) POLBNPSR1ALDH1A1KDM4EGLA
SCHEMBL18221467 0.85 KDM4E (0.35) WNT3AFYNCNR2POLBNPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240208916-A1 AMYLOID TARGETING AGENTS AND METHODS OF USING THE SAME Amydis, Inc. 2024-06-27 US disclosed
US-11718596-B2 Amyloid targeting agents and methods of using the same THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2023-08-08 US disclosed
US-10005745-B2 Amyloid targeting agents and methods of using the same THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2018-06-26 US disclosed
US-20170248616-A1 IN VITRO COMPOSITIONS COMPRISING HUMAN SAMPLE AND AMYLOID TARGETING AGENT Amydis, Inc. 2017-08-31 US disclosed
US-20160326126-A1 AMYLOID TARGETING AGENTS AND METHODS OF USING THE SAME Amydis, Inc. 2016-11-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11718596-B2 Amyloid targeting agents and methods of using the same APP, CRYAA, APBA1 WNT3A 4408/4885FYN 1545/4885CNR2 4195/4885
US-20240208916-A1 AMYLOID TARGETING AGENTS AND METHODS OF USING THE SAME APP, CRYAA, APBA1 WNT3A 4408/4885FYN 1545/4885CNR2 4195/4885
US-20160326126-A1 AMYLOID TARGETING AGENTS AND METHODS OF USING THE SAME APP, APBA1, CRYAA WNT3A 4441/4885FYN 1515/4885CNR2 4290/4885
US-10005745-B2 Amyloid targeting agents and methods of using the same APP, APBA1, CRYAA WNT3A 4441/4885FYN 1515/4885CNR2 4290/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.